CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 23, 2015--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and rare diseases and T cell-based immunotherapies, today announced that
it has commenced an underwritten public offering of $400 million of its
common stock. bluebird bio also intends to grant the underwriters a
30-day option to purchase up to an additional fifteen percent (15%) of
the shares of common stock offered in the public offering.
BofA Merrill Lynch, Morgan Stanley and Cowen and Company are acting as
joint book-running managers of the proposed offering. SunTrust Robinson
Humphrey, Wedbush PacGrow and Roth Capital Partners are acting as
co-managers. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the SEC’s
website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: BofA Merrill Lynch, 222
Broadway, New York, NY 10038, Attn: Prospectus Department, or via email,
Morgan Stanley, Attn: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014; or Cowen and Company, LLC, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn:
Prospectus Department. The final terms of the offering will be disclosed
in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and T cell-based
immunotherapy. bluebird bio’s clinical programs include Lenti-D™,
currently in a Phase 2/3 study, called the Starbeam Study, for the
treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®,
currently in three clinical studies: a global Phase 1/2 study, called
the Northstar Study, for the treatment of beta-thalassemia major; a
single-center Phase 1/2 study in France (HGB-205) for the treatment of
beta-thalassemia major or severe sickle cell disease; and a separate
U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206).
bluebird bio also has ongoing preclinical CAR T immuno-oncology
programs, as well as discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, and Paris, France.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the proposed public offering, that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk that previously conducted studies involving similar
product candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in our clinical studies, the risk that our
collaboration with Celgene will not continue or will not be successful,
and the risk that any one or more of our product candidates will not be
successfully developed and commercialized. There can be no assurance
that bluebird bio will be able to complete the proposed public offering
on the anticipated terms, or at all. For a discussion of other risks and
uncertainties, and other important factors, any of which could cause our
actual results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and bluebird bio
undertakes no duty to update this information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006535/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Pure Communications, Inc.
Dan Budwick, 973-271-6085